Melissa Burt - Associate Director, HTA and Clinical Evaluation
PhD, Integrated Program in Neuroscience, McGill University, Montreal, Quebec, Canada
MSc, Biology, University of Prince Edward Island, Charlottetown, PEI, Canada
Dr. Melissa Burt is an Associate Director, HTA and Clinical Evaluation at PDCI. Her role involves the development of clinical documents and components of reimbursement and pricing submissions, as well as market access and pricing assessments. This involves evaluating and summarizing scientific information and providing strategic guidance based on the Canadian market access landscape.
Melissa joined PDCI in 2017 as an Associate and has worked on a wide range of disease states and products. Prior to joining PDCI, she had over 8 years of preclinical research experience with a strong background in neurodevelopment and neurobiological disorders. She previously worked as a Senior Medical Writer at IC Axon in Montreal, where she developed training materials for pharmaceutical and biotechnology companies including global launch training curriculums and live meetings.